Welcome to our dedicated page for SHUTTLE PHARMACTCLS HLDGS news (Ticker: SHPH), a resource for investors and traders seeking the latest updates and insights on SHUTTLE PHARMACTCLS HLDGS stock.
Shuttle Pharmaceuticals Holdings Inc (SHPH) is a clinical-stage biopharmaceutical company pioneering radiation-enhancing therapies for cancer treatment. This page provides investors and researchers with timely updates on clinical trials, regulatory milestones, and scientific advancements related to their novel radiation sensitizers and HDAC inhibitors.
Access verified press releases and news about SHPH's pipeline developments, including Ropidoxuridine for glioblastoma and SP-1-303 research. Our curated collection helps stakeholders track progress of therapies designed to improve radiation effectiveness while protecting healthy tissues.
Discover updates on Phase 2 trials, partnership announcements, and peer-reviewed research findings. Content is rigorously verified to ensure accuracy across all stages of drug development – from preclinical studies to regulatory submissions.
Bookmark this page for streamlined access to SHPH's latest innovations in oncology treatment. Check regularly for new developments in their mission to enhance radiation therapy outcomes through targeted pharmaceutical solutions.
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) announced a research agreement with Georgetown University to evaluate its lead HDAC6 inhibitor candidate, SP-2-225. The collaboration will focus on the anti-tumor effects of SP-2-225 in combination with radiation therapy (RT) using a breast cancer model. The research aims to support IND-enabling studies in 2023 with plans for a Phase I clinical trial in 2024. SHPH's pipeline includes Ropidoxuridine, aimed at enhancing cancer cell sensitivity to RT, which is progressing towards Phase II testing in brain cancer patients. This partnership underscores SHPH's commitment to improving cancer treatment outcomes.
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) reported a corporate update on March 15, 2023, in conjunction with its Annual Report on Form 10-K for the fiscal year ending December 31, 2022. The company raised $11.5 million through its IPO and $4.3 million through a private placement. It is preparing for a Phase II clinical trial of its lead drug candidate, Ropidoxuridine, aimed at enhancing outcomes for glioblastoma patients undergoing radiation therapy. With a cash balance of $8.4 million as of December 31, 2022, and recent funding, Shuttle anticipates sufficient capital to support operations through Q4 2025.
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) announced a partnership with the University of Iowa Pharmaceuticals for the formulation development and clinical batch manufacturing of Ropidoxuridine. This step is crucial for their upcoming Phase II clinical trial aimed at glioblastoma treatment, expected to be submitted to the FDA by Q2 2023. The company has manufactured approximately 10,000 capsules for the trial, working alongside TCG GreenChem, Inc. With over 800,000 patients annually receiving radiation therapy in the U.S., Shuttle's focus on radiation sensitizers positions it to address significant market needs in oncology.
FAQ
What is the current stock price of SHUTTLE PHARMACTCLS HLDGS (SHPH)?
What is the market cap of SHUTTLE PHARMACTCLS HLDGS (SHPH)?
